Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Thursday reported a net loss for the first quarter of 2026. Revenues increased 12.2% on a year-over-year basis.
- Net sales for the first quarter increased 12.2% year-over-year to $75.7 million; Med Tech sales grew 26% to $35.3 million
- At $40.4 million, Med Device sales were up 2.3% in Q1, compared to $39.5 million in the prior-year period
- The company recorded a net loss of $10.9 million or $0.26 per share for Q1, vs. a loss of $12.8 million or $0.31 per share last year
- Excluding special items, adjusted net loss was $4.2 million or $0.10 per share, compared to $4.4 million or $0.11 per share in Q1 2025
- Adjusted EBITDA, excluding one-off items, was $2.2 million, compared to a loss of $0.2 million in the first quarter of 2025
- The management said it continues to expect to be cash flow positive for the full fiscal year 2026
- The company raised its FY26 net sales guidance to $308-313 million from the earlier outlook of $305-310 million
- It now expects a loss per share in the range of $0.33 to $0.23 for FY26, compared to the previous forecast for a loss per share between $0.35 and $0.25